Cardiac event rate in a lifestyle modification program for patients with chronic coronary artery disease

Clinical Cardiology

Volumn 29, Issue 7, 2006, Pages 317-321

  Kappagoda, C Tissa ^a,b   Ma, Amy ^a   Cort, Douglas A ^a   Paumer, Linda ^a   Lucus, Debbie ^a   Burns, Jill ^a   Amsterdam, Ezra ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiac rehabilitation; Coronary artery disease; Lifestyle changes

Indexed keywords

LIPID;

ADULT; ANGIOGRAPHY; ARTICLE; BLOOD PRESSURE; CHRONIC DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET THERAPY; EXERCISE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; LIFESTYLE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PATIENT EDUCATION; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; STRESS; STROKE; TREATMENT OUTCOME;

AGED; CHRONIC DISEASE; CORONARY DISEASE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS;

EID: 33745927422     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960290709     Document Type: Article

References (15)

1. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S, and the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators: Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-1687
2. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, and the REPLACE-2 Investigators: Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs. heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. J Am Med Assoc 2004;292: 696-703
3. Law MR, Wald NJ, Rudnicka AR: Quantifying effects of statins on low density lipoprotein, cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Br Med J 2003;326:1-7
4. Dagenais GR, Yusuf S, Bourassa MG, Yi Q, Bosch J, Lonn EM, Kouz S, Grover J, and the HOPE Investigators: Effects of ramipril on coronary events in high-risk persons: Results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001;104:522-526
5. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RI, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 2004;110:588-636
6. No Author Listed. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285,2486-2497
7. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, Budaj A, Álvaro Avezum A, Marcus D, Flather MD, Fox KAA: Validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry. J Am Med Assoc 2004;291:2727-2733
8. Ornish D, Brown S, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLAnahan SM, Kirkeides RL, Brand RJ, Gould KL: Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336:129-133
9. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ: Intensive lifestyle changes for reversal of coronary heart disease. J Am Med Assoc 1998;280:2001-2007
10. Gould KL, Ornish D, Scherwitz L, Brown S, Edens RP, Hess MJ: Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. J Am Med Assoc 1995;274: 894-901
11. Sdringola S, Nakagawa K, Nakagawa Y, Yusuf SW, Boccalandro F, Mullani N, Haynie M, Hess MJ, Gould KL: Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol 2003;41:263-272
12. Lacroix A, Assal J-P: Therapeutic Education of Patients. 2nd ed. Paris: Editions Maloines; 2003
13. Rutledge JC, Hyson DA, Garduno D, Cort DA, Paumer L, Kappagoda CT: Lifestyle modification program in management of patients with coronary artery disease: The clinical experience in a tertiary care hospital. J Cardiopulm Rehabil 1999;19:226-234
14. Heart Protection Study Collaborative Group: MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003;361:2005-2016
15. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, and the Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403